Zhejiang Hisun Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang Haizheng Pharmaceutical Co., Ltd. was founded in 1956 and was listed on A-shares in 2000. It is a state-owned listed company. After more than 60 years of development, Haizheng Pharmaceutical has become a comprehensive pharmaceutical enterprise group that integrates research, production, and sales along the entire value chain, as well as vertical integration of raw materials and formulations. The company focuses on the development of multiple industries such as chemical medicine, biopharmaceuticals, animal medicine, traditional Chinese medicine, and commercial circulation, accelerating the layout of emerging markets such as the big health industry and health aesthetics. It has been repeatedly selected as one of the top 500 manufacturing enterprises in China and one of the top 100 pharmaceutical industry enterprises in China, and has been awarded honorary titles such as the National Technology Innovation Demonstration Enterprise, the National May Day Labor Award, and the Zhejiang Provincial Government Quality Award. As one of the first batch of innovative enterprises in the country, Haizheng Pharmaceutical has a high-level and multi-dimensional research and development platform. It has established research and development centers in Taizhou headquarters, Shanghai, Hangzhou, the United States, and other places. It also has a national level enterprise technology center, the first batch of independent postdoctoral research workstations in Zhejiang Province, and first-class research and development platforms such as Zhejiang Provincial Key Laboratory. It has a full chain of drug research and development capabilities. In 2021, the first innovative drug independently developed by the company, Haibo Maibu Tablets, was approved and launched. It is the only Class 1 new drug approved in the cardiovascular field in China in recent years and has been selected for the "14th Healthy China Annual Forum · Top 10 New Drugs (Domestic) List". In terms of biopharmaceuticals, a rich product pipeline has been established in the fields of autoimmune and tumor therapy. 5 products have been approved for launch, more than 10 products are in clinical use, and multiple products are in preclinical research. The first insulin product, insulin aspartate, has been approved and won the bid for national procurement. In recent years, we have undertaken more than 50 national major new drug creation special projects, won more than 10 provincial and ministerial level scientific and technological progress awards, applied for more than 1100 patents, obtained more than 500 authorized patents, and won 6 invention patents such as the "China Patent Excellence Award". Haizheng Pharmaceutical, with the spirit of craftsmanship, creates high-quality drugs and takes the lead in creating a QEHS management system in China. Its products have passed the global medical quality high standard system inspection, introduced advanced equipment from home and abroad, and built more than 80 international first-class advanced preparation production lines, implementing online automatic control throughout the entire process. As the first local pharmaceutical enterprise in China to achieve localized production of original research drugs, Haizheng has a leading CSO platform with advanced pharmaceutical foundation in China, forming new marketing formats such as professional chemical technology promotion based on compliance systems, online and offline digital and intelligent three-dimensional marketing, customized R&D and production for global pharmaceutical enterprises, and supporting collaborative development of innovative pharmaceutical enterprises. The company's international sales network covers over 70 countries and regions worldwide, with over 10000 domestic drug admissions. Currently, more than 40 products have passed or deemed to have passed consistency evaluations, and more than 10 drugs have been selected for national centralized procurement, significantly reducing the cost of medication for patients. As a state-owned enterprise with a sense of responsibility and mission, Haizheng actively undertakes major national strategic needs. Products such as Tamiflu, anti Ebola drugs, anti super resistant bacteria tigecycline, and anti tuberculosis drug cycloserine help patients in multiple countries, demonstrating Haizheng's responsibility and responsibility as a national pharmaceutical enterprise. During the epidemic period, the company's production of Faviravir tablets was quickly approved for listing, helping the global fight against the epidemic. We have received multiple thank-you letters from the Joint Prevention and Control Group of the State Council, the Ministry of Science and Technology of China, and the Medical Supplies Support Group of Zhejiang Province, and have been praised as a well-deserved "military factory" in the fight against the epidemic. Over 60 years of development have accumulated the profound foundation of the Haizheng brand. Haizheng Pharmaceutical will be guided by patient needs, based on a refined management system, with integrated research, production, and sales operations as the framework, a professional talent team as the energy, and continuous practical innovation as the driving force to deliver world-class quality, showcase Haizheng's new face, and build a new brand of national good heart pharmaceutical. |
| Headquarter | Taizhou |
| Establish Date | 2/11/1998 |
| Listed Code | 600267.SH |
| Listed Date | 7/25/2000 |
| Chairman | Shen Xinghu. |
| CEO | Yang Zhiqing. |
| Website | www.hisunpharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
